

1 **Title:** The health impact of social exclusion: a systematic review and meta-analysis
2 of morbidity and mortality data from homeless, prison, sex work and substance use
3 disorder populations in high-income countries.

4
5 **Authors:** Robert W Aldridge PhD^{1,2*}, Alistair Story PhD^{1,2,3}, Prof Stephen W Hwang
6 MD⁴, Prof Merete Nordentoft DMSc⁵, Serena A Luchenski MFPH^{1,2}, Greg Hartwell
7 MFPH⁶, Emily J Tweed MFPH⁷, [Dan Lewer MFPH^{1,2}](#), Srinivasa Vittal Katikireddi
8 PhD⁷, Prof Andrew C Hayward MD^{1,2,8}

9
10 1. Centre for Public Health Data Science, Institute of Health Informatics, University
11 College London, 222 Euston Road, London, NW1 2DA, UK.

12 2. The Farr Institute of Health Informatics Research, University College London, 222
13 Euston Road, London, NW1 2DA, UK.

14 3. University College London Hospitals, London, UK.

15 4. Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St Michael's
16 Hospital, Toronto, ON, Canada

17 5. Mental Health Centre Copenhagen and Faculty of Health and Medical Sciences,
18 University of Copenhagen, Denmark

19 6 Department of Social and Environmental Health Research, London School of
20 Hygiene & Tropical Medicine, London WC1H 9SH, UK

21 7. MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Top floor,
22 200 Renfield Street, G2 3QB, UK.

23 8. Institute of Epidemiology and Health Care, University College London, 1 - 19
24 Torrington Place, London WC1E 6BT, UK.

25
26 *Corresponding Author

27 Robert W Aldridge

28 The Farr Institute of Health Informatics Research

29 University College London

30 222 Euston Road

31 London NW1 2DA

32 Email: r.aldridge@ucl.ac.uk

33 Telephone: +44 20 3549 5541

34

35

36

37 **Abstract**

38 **Background:**

39
40 Inclusion health focuses on people in extremes of poor health due to poverty,
41 marginalisation and multiple morbidity. We aimed to synthesise morbidity and
42 mortality data on overlapping populations experiencing deep social exclusion evident
43 by homelessness, substance use disorders, sex work and imprisonment.
44

45 **Methods:**

46
47 We searched Medline, Embase and the Cochrane Library for studies published
48 January 2005-October 2015. We included articles written in English from high-
49 income countries that were conducted in populations with histories of homelessness,
50 imprisonment, sex work and substance use disorder (excluding cannabis and
51 alcohol). Primary outcomes were measures of morbidity (prevalence or incidence)
52 and mortality (standardised mortality rates – SMRs – and mortality rates).
53

54 **Findings:**

55
56 Our search identified 7946 articles, with 337 studies included. All-cause SMRs were
57 significantly raised in 98.9% (91/92) of extracted data points and were 11.9 (95% CI
58 10.4–13.3; I² 94.1%) in females and 7.9 (95% CI 7.0–8.7; I² 99.1%) in males.
59 Heterogeneity was high between studies. Summary SMR estimates for ICD-10
60 categories with two or more included data points were highest in deaths due to injury
61 and poisoning in males (7.9; 95% CI 6.4-9.4; I² 98.1%) and females (18.7; 95% CI
62 13.7-23.7; I² 91.5%). Disease prevalence was consistently raised across infections,
63 mental health, neoplasms, cardiovascular, gastroenterological and respiratory
64 conditions.
65

66 **Interpretation:**

67
68 Socially excluded populations experience extreme health ~~inequalities~~inequities; far
69 greater than those observed amongst people living in areas of high social
70 deprivation. These ~~inequalities~~inequities occur across the full spectrum of health
71 conditions, with the relative impact of exclusion being greater in females than males.
72 Measures of morbidity and mortality were much higher than those observed across
73 area based measures of social deprivation highlighting the need for better data on
74 these populations who are largely invisible in routine health information systems. The
75 extreme health inequity demonstrated demands intensive cross sectoral policy and
76 service action to prevent exclusion and improve health outcomes in those already
77 marginalised.
78

79 **Funding**

80 Wellcome Trust, NIHR, NHSE, NRS Scottish Senior Clinical Fellowship, Medical
81 Research Council, Chief Scientist's Office, Central and North West London NHS
82 Trust.
83
84

85 Introduction

86
87 Inclusion health is a research, service, and policy agenda that aims to prevent and
88 redress health and social inequities among people in extremes of poor health due to
89 poverty, marginalisation and multiple morbidity (cross reference IH paper 2). It is well
90 established that in high income countries, health outcomes are strongly influenced
91 by socioeconomic status. The association between socioeconomic status and health
92 outcomes is well established. For example, the standardised mortality rates for
93 those aged 15–64 in the most deprived twentieth of areas-neighbourhoods of in
94 England are 2.8 times the rate in the least deprived areas-neighbourhoods for men
95 and 2.1 times the rate for women.¹ However, analyses based on geographical
96 location may obscure these commonly observed social gradients in health may not
97 capture the true extent of health inequities in-for those who-experiencing deep
98 social exclusion.⁴

99
100 Previous research has described the high levels of substance use disorders (SUD) in
101 homeless populations², prisoners³, and sex workers⁴, and the increased prevalence
102 of homelessness in prisoners⁵ and sex workers⁶. These marginalised populations
103 have common intersecting characteristics and adverse life experiences that lead to
104 deep social exclusion, making them some of the most common powerful
105 determinants of marginalisation in high-income settings.⁷

106
107 Marginalised populations when considered separately have been shown to have
108 high levels of all-cause mortality.^{8–10} However, despite the highly overlapping nature
109 of the risk factors and substantially increased mortality, no previous review has
110 attempted to examine their outcomes together.

111
112 No universally agreed theoretical framework describes inclusion health. However,
113 we build on existing social exclusion theory and consider the “linked and
114 cumulative factors” and processes that confound individual and group capacity for
115 hope, opportunity, reciprocity and participation.¹¹ Our analysis is also informed by
116 an intersectionality perspective, which focuses on how social characteristics combine
117 to impact on health.^{2,12}

118
119 Our systematic review examines the health outcomes mortality and morbidity in four
120 overlapping populations together as exemplar determinants of deep exclusion. We
121 aimed to systematically review and meta-analyse mortality and morbidity in
122 homeless, prison, sex work, and SUD populations jointly for the first time.

123 Methods

124 We searched the Cochrane Library, Medline and Embase from 1 January 2005 and
125 to 1 October 2015 on 27 October 2015. Full search terms are provided in the
126 supplementary appendix. We searched for papers about the populations of interest
127 (homeless, prison, sex workers and SUD) from systematic reviews, meta-analyses,
128 interventional and observational studies with morbidity and mortality outcomes. We
129 included studies identified from references of included articles.

130
131 We recognise that social exclusion has a major impact on health in other groups,
132 such as Gypsies and Travellers and vulnerable migrants, ethnic minorities, indigenous

133 communities and sexual and gender minorities, most notably transgender populations. Whilst these groups experience
134 social exclusion in many high-income settings, they were considered beyond the
135 scope of this review.

136
137 RWA screened titles, abstracts and full texts using Covidence systematic review
138 software (<https://www.covidence.org/>). All authors contributed to data extraction
139 ~~(conducted using a Google Docs <https://docs.google.com/>)~~ and data were double-
140 checked by a second researcher (RWA, ET, GH or SVK). Extracted items included
141 study design, year(s) of study, country, number of participants, primary outcome(s),
142 and summary description of the study population. We attempted to contact authors if
143 we were unable to locate papers, or required additional information about the data or
144 study.

145
146 We attempted to identify and exclude duplicate data from research studies presented
147 in separate publications. Where we identified multiple studies with duplicated or
148 overlapping data (by population, time, place and outcome) we chose the study with
149 the largest or most representative sample size, and when these were also similar,
150 we present the most recent study. We followed the PRISMA reporting guidelines in
151 the presentation of our manuscript. A review protocol was not published prior to
152 conducting the review.

153 154 **Outcomes**

155
156 Outcomes included were measures of morbidity and mortality for ICD-10 defined
157 conditions. Papers use a variety of measures to report outcomes. In order to ensure
158 maximum comparability across studies for mortality outcomes, we extracted, in order
159 of preference the first of: ~~the first reported measure out of the following:~~ SMRs,
160 relative hazard ratio, mortality rate ratio, or crude mortality rate. For consistency
161 with the majority of studies included in the review, we have not multiplied SMRs by
162 100. In our results a value of 1 equates to no difference between the expected and
163 observed mortality rate. For morbidity outcomes, we extracted, in order of preference
164 the first of: prevalence, incidence, prevalence risk ratio (~~PRR~~), incidence rate ratio
165 (~~IRR~~), prevalence odds ratio (~~POR~~), or incidence odds ratio (~~IOR~~). Where available,
166 we used data where the comparison group was selected as a socially deprived
167 population or measures adjusted for area-based or income-based deprivation.

168 169 **Statistical analysis**

170
171 We include all extracted data in an online supplementary appendix. For the
172 quantitative findings analysed in the paper we focus the synthesis on the primary
173 outcome of SMRs. SMRs for all-cause mortality and by ICD-10 chapter were
174 summarised in forest plots. We anticipated high levels of heterogeneity a-priori, and
175 therefore created summary estimates using random effects models using Stata v.13
176 (Statacorp LP, College Station, TX, USA). We used the I^2 transformation to describe
177 the proportion of total variation in study estimates due to heterogeneity.¹⁴ We
178 explored potential sources of heterogeneity by stratifying the analyses by country
179 and by inclusion health population group. We describe the results of studies of
180 disease prevalence individually. We report summary estimates of morbidity and
181 mortality of recently published meta-analyses found by our search within our results
182 and did not attempt to update each of these within our review. In addition to our

~~quality, health, and social factors, and the role of funding sources in the decision to submit the manuscript for publication.~~

Role of the funding source

The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. All authors had access to all the data, and were responsible for the decision to submit the manuscript.

Results

~~We~~ A search of the bibliographic databases was conducted on 27th October 2015 and identified 7,946 articles with 1,274 duplicate articles ~~then excluded~~ (Figure 1). Of the 711 full text articles retrieved, 418 met the inclusion criteria, ~~but a~~ We excluded a further 81 ~~were excluded~~ due to overlapping data. A total of 337 studies were included in the review, with including 3,219 'data points' (meaning an result effect estimate for a unique population) ~~extracted and~~ 2,835 ~~included~~ after removal of duplicates.

The ~~included studies presented data from 38 out of 80 high-income countries (Figure 2)~~ studies were from 38 countries (See Figure S1 in supplementary appendix). USA (698 data points), Australia (460), Sweden (309), Canada (257), and United Kingdom (234) ~~were the five countries with had~~ the highest number of ~~most data~~ data points (number in brackets for each) ~~included in the review after de-duplication~~. SUD populations were the most studied sub-group groups, accounting for ~~contributing to~~ 42.1% (1,192/2,835) of ~~all data points (after de-duplication)~~, followed by prisoners (27.1%; 769/2,835), homeless (26.6%; 754/2,835) and sex workers (4.2%; 119/2,835).

Infectious diseases and mental and behavioural disorders were the two most studied ICD-10 chapters with a total of 897 (31.6%; 897/2,835) and 715 (25.2%; 715/2,835) ~~included~~ data points respectively (Figure 3~~2~~). Injury and poisoning only contributed 3.4% (98/2,835) of all extracted data points.

~~Our meta-analyses focused on SMRs ((Tables 1 and 2 and Figures 3, 4, and 5)). The most studied causes of death were 'all-cause' ((XX% of data points)) and 'injury, poisoning and external causes' ((XX% of data points)). Most studies in the meta-analysis were of SUD groups, including ((XX% (XX/XX))) studies of all-cause mortality. Cause-specific studies in males and females were split between prisoners and SUD groups, while cause-specific studies for both sexes combined were in SUD groups only. There were only (three) studies of homeless people included in the meta-analysis and none of FSW.~~

Our all-cause meta-analyses focused on SMRs, with 31 studies¹⁰ contributing 92 data points (Table 1 & Figures 3, 4 & 5). 98.9% (91/92) of all included all-cause SMRs were increased and overall we estimated that summary all-cause SMRs were higher in females 11.9 (95% CI 10.4–13.3; I² 94.1%) than males 7.9 (95% CI 7.0–8.7; I² 99.1%). We provide summary estimates of SMRs, however, data were heterogeneous as measured by the I² statistic in many of our analyses (which we have explored further and therefore these summary measures must be interpreted with appropriate caution. Heterogeneity was not substantially reduced when

Commented [RA1]: Add before submission

Commented [DL3]: Why is this reference here?

Commented [RA4R3]: Should be all 31 studies – update before submission

230 analyses by population subgroup were undertaken. Insufficient data were available
231 to conduct subgroup analyses by country.

232 Summary SMRs were higher in females than in males for all-cause mortality and
233 mortality in each of the ICD-10 chapters. In some ICD-10 chapters, the summary
234 SMR for both sexes combined did not fall between the male and female estimates.
235 This is because the meta-analyses draw on different studies (rather than the
236 estimate for both sexes combined being drawn from the same male and female
237 populations).

240
241 Infectious and parasitic diseases were the most studied disease conditions in
242 inclusion health populations and we identified 201 papers contributing to 31.6%
243 (897/2,835) of all data extracted (Table 2). Summary estimates of SMRs for
244 infectious diseases were raised for males (2.8; 95% CI 1.6-4.1; I² 65.4%) and
245 females (5.6; 95% CI 1.5-9.7; I² 60.0%). Disease prevalence was high but
246 heterogeneous. HIV ranged from 0%(0/146)¹⁵ to 61.5% (44/69)¹⁶, Hepatitis C from
247 0.1% (1/734)¹⁷ to 92.8% (64/69)¹⁶, Hepatitis B from 1.7% (2/119)¹⁸ to 65.0%
248 (67/103)¹⁹, and latent tuberculosis infection from 1.2% (1/82)²⁰ to 50.6% (133/263)²¹.

249
250 It was estimated that 2.2 million prisoners globally were hepatitis C positive with the
251 largest populations in North America (668,500).²⁸ A meta-analysis of the prevalence
252 of sexually transmitted infections (STIs) in prisoners found marked wide variation
253 and reported a pooled prevalence for Chlamydia of 5.8% (95% CI 5.0-6.5%) in men
254 and 12.3% (95% CI 10.6-14.0%) in women; gonorrhoea, 1.4% (95% CI 1.1-1.7%) in
255 men and 5.7% (95% CI 4.8-6.7%) in women; and syphilis, 2.5% (95% CI 2.1-2.8%)
256 in men and 6.1% (95% CI 4.8-7.5%) in women.²⁹

257
258
259
260 SMRs for males and females were exclusively from prison populations. SMR data for
261 both sexes combined were from SUD populations only, with all subgroups by sex
262 having fewer than three studies included.

263 **Other non-communicable diseases**

264
265 Summary estimates of SMRs due to neoplasms were raised in males (1.6; 95% CI
266 1.3-1.9; I² 88.7%), females (1.9; 95% CI 1.3-2.5; I² 62.8%) and both sexes combined
267 (2.2; 95% CI 1.6-2.8; I² 90.6%).

268 In homeless adults in Toronto, 59% had moderate, severe or very severe symptoms
269 of dyspepsia (around twice as many as in the general population).⁵² In prisoners in
270 the USA, 4.9% of male and 9.6% of females had a history of hepatitis and 1.2% of
271 men and 2.1% of women had a history of cirrhosis.⁵³ A dental survey of inmates in a
272 juvenile detention facility in Texas showed higher Decayed, Missing or Filled scores
273 than age and ethnicity matched population controls.⁵⁴ Dental health problems were
274 also common in homeless people.⁵⁵

275
276
277 The available body of evidence is largest for infectious diseases, with considerable
278 existing research on morbidity associated with mental and behavioural disorders. In

279 contrast, there is a relative paucity of evidence on non-communicable diseases and
280 injury, poisoning and external causes despite these causes having the highest SMRs
281 across ICD-10 categories. SMRs across disease categories were consistently higher
282 in females than males. Of the four inclusion health populations considered, sex
283 workers were the least well investigated, which should be addressed as a matter of
284 priority.

285
286 Our study comprehensively describes for the first time the relative mortality and
287 morbidity burden in selected inclusion health populations. We have synthesised the
288 significant existing literature in this area using a comprehensive search strategy to
289 identify the current balance of evidence available to inform policymaking around
290 inclusion health. Data were extracted and reviewed by a second author reducing the
291 likelihood of errors. Our approach has allowed us to identify relative gaps in terms of
292 both categories of disease and inclusion health categories. Our analysis was
293 informed by an intersectionality perspective, which focuses on how social
294 characteristics in combination impact on health.^{7,31} We have therefore specifically
295 investigated how the health consequences of exclusion may vary by other socially
296 influenced characteristics, with differences by gender particularly noteworthy.

297
298 A number of limitations should be considered. Caution must be taken when
299 interpreting the summary estimates of SMRs due to ~~the high level of the~~
300 ~~heterogeneity found of studies.~~ A lack of internationally agreed definitions ~~for the~~
301 ~~populations considered in this review means of inclusion health groups, there is~~
302 ~~variation in the levels of risk for included studies which~~ is likely to explain some of
303 this variation. Similarly, comparison groups varied, with some studies ~~comparing to~~
304 ~~general population estimates and others to those from socially deprived areas using~~
305 ~~the general population and others using groups living in socially deprived areas.~~
306 Studies also varied according to the extent ~~that analyses adjusted of adjustment~~ for
307 social deprivation and other risk factors. ~~However, w~~We have utilised ~~used~~ a
308 random-effects methods ~~to model the data appropriately~~ and note existing
309 recommendations that meta-analysis should be pursued whenever possible, ~~with~~
310 ~~appropriate acknowledgement of its limitations when acknowledging~~ heterogeneity is
311 high.³² We limited our search to 2005 onwards and therefore ~~longer term time trends~~
312 ~~are not possible to examine with this analysis~~we have not examined longer-term
313 ~~trends.~~ Furthermore, there is a need for future investigation of how contextual
314 ~~factors, such as a country's social policies, influence health outcomes for excluded~~
315 ~~groups.~~ Lastly, for pragmatic reasons, we were unable to investigate ~~many other~~
316 ~~dimensions of social exclusion.~~ We therefore ~~other~~ health inclusion groups and
317 believe that further work is required to ~~investigate the health experiences of other~~
318 ~~socially excluded groups describe their health experiences.~~

319
320 We found consistently higher SMRs for females than males. Since general
321 population mortality rates are lower in women than men for most conditions this does
322 not necessarily indicate worse outcomes in women in inclusion health groups
323 compared with men. -It may ~~however~~ reflect an increased vulnerability of women in
324 inclusion health populations ~~or different risk distributions among women and men in~~
325 ~~inclusion health groups. SMR is a relative measure and the lower SMRs for common~~
326 ~~conditions such as cardiovascular disease and cancer may underplay the number of~~
327 ~~excess cases. Conversely, high SMRs may not indicate a large number of excess~~

328 cases if the condition is rare. Further work should report absolute as well as relative
329 measures of mortality.
330 ~~SMR is a relative measure, consequently less extreme SMRs seen for common~~
331 ~~conditions such as cardiovascular disease and cancer may underplay the~~
332 ~~importance of these outcomes at a population level. Conversely high SMRs for rare~~
333 ~~conditions may inflate their apparent relevance. Further work should report absolute~~
334 ~~as well as relative measures of mortality for different conditions to enable a better~~
335 ~~assessment of the contribution of different causes of mortality.~~
336 These extreme ~~inequalities~~ inequities demand an intensive cross-sectoral policy and
337 service response to prevent exclusion and improve health outcomes. An
338 accompanying review ([cross reference IH paper 2](#)) outlines interventions that
339 respond to these increases in morbidity and mortality. ~~Here we focus on research~~
340 ~~recommendations in relation to disease burden measurement to address issues~~
341 ~~identified by our review and we briefly discuss the health system response.~~
342
343 Determining the burden of disease remains challenging in inclusion health
344 populations as membership of an inclusion health population is not recorded in most
345 vital registration and health information systems. Deaths and health service usage in
346 excluded populations are therefore a largely invisible and neglected problem as far
347 as routine statistics are concerned. By contrast, the availability of area-based
348 measures of social deprivation across high income countries has allowed
349 measurement of the major population level impact of less extreme social inequalities.
350 This has supported extensive cross sectoral policy initiatives to address these
351 inequalities.³³ Better routine data is also needed to drive the policy response to the
352 inclusion health agenda.
353
354 There are two broad potential approaches to tackling ~~the lack of routine mortality and~~
355 ~~health service data for inclusion health groups~~ this problem. ~~Routinely recording~~
356 ~~membership of inclusion health groups in health and mortality records is a~~
357 ~~possibility~~ Firstly, health services could routinely record membership of health
358 inclusion groups. This would require ~~clear agreed~~ clearly agreed definitions of ~~excluded populations~~
359 ~~each group to be agreed along with standard outcome measures~~. Those responsible
360 for recording data would need ~~clear~~ clear guidance to help them ascertain membership of
361 ~~inclusion health groups and sensitivity would be needed to ensure this does not~~
362 ~~reinforce~~ avoid reinforcing of existing stigma for socially excluded groups.³⁴ The
363 feasibility of ~~routinely recording membership of these inclusion health groups~~ this
364 approach outside the context of specialist services remains unclear. Alternatively,
365 and more feasibly in the short term, data linkage ~~methodologies~~ methods could be
366 used to match data from services that work with ~~excluded populations~~ inclusion
367 health groups, with vital registration data, electronic health records, and existing
368 ~~infectious and non-communicable disease surveillance systems~~.³⁵ ~~These linked~~
369 ~~datasets would then facilitate systematic estimates of mortality and morbidity over~~
370 ~~time~~. This has been the primary method used to estimate SMRs in the studies
371 reported in this paper. These linked datasets would facilitate systematic estimates of
372 mortality and morbidity over time and help to measure the impact of
373 interventions. ~~Routine linkage of such datasets could facilitate systematic estimates~~
374 ~~of mortality and morbidity over time and help to measure the impact of policies and~~
375 ~~interventions.~~
376

377 As part of this wider Lancet Series we held an engagement workshop with people
378 with lived experience of homelessness and social exclusion (described in more detail
379 in paper 2). We asked this group about their views on collecting operational data with
380 ethical and appropriate research governance approvals, but without specific
381 individual level consent. Although this was only a small sample (and we
382 acknowledge that people who face exclusion and are willing to come in to a
383 workshop may differ from those who do not) acceptability of collection of this sort of
384 data was extremely high. 100% of users were happy for homeless hostel records to
385 be collected, 73% agreeing to the collection of criminal records, 62% to health
386 records, and 85% agreeing to these records being linked together.

387
388 A vertical approach to tackling inclusion health (i.e. one that focusses on specific
389 diseases or specific risk groups) can ~~ignore and neglect~~ overlook multiple morbidity
390 and the social issues faced by excluded populations.³⁶ This can result in
391 inefficiencies and missed opportunities for prevention, early diagnosis and
392 management as well as missed opportunities for mitigation of social risk factors. The
393 emerging field of inclusion health should advocate for and deliver joined up health
394 and social services for overlapping marginalised groups. These services should
395 address not only diseases with extreme disparities, but also prevention and
396 management of more common conditions with a lower relative risk but ~~high disease~~
397 ~~burden~~ large numbers of excess cases, such as cardiovascular disease. The ability of
398 health and social policy to address the needs of the most marginalised populations
399 should be a key indicator of quality. Such initiatives need to be supported by ~~robust~~
400 information systems that can provide data for continuing advocacy, guide service
401 development and monitor the health of marginalised populations over time.

402 403 **Research in context**

404 405 *Evidence before this study*

406 There is a comprehensive body of research on the health impact of
407 ~~inequality inequity~~, much of which focusses on disparities in morbidity and mortality,
408 and is based on ~~area based measures of social deprivation~~ common measures of
409 ~~socioeconomic status such as neighbourhood deprivation and occupational class~~.
410 The evidence of a consistent relation between ill health and increasing levels of
411 social deprivation has underpinned a broad range of social policies and public health
412 initiatives. Such ~~geographical based~~ analyses cannot adequately assess the extent
413 of health ~~inequalities inequity~~ experienced by those experiencing deep social
414 exclusion. In preparation for the inclusion health series we searched the Cochrane
415 Library, Medline and Embase from 2000 to 30th September 2013. We searched for
416 systematic reviews, meta-analyses, cohort and cross-sectional studies containing
417 morbidity and mortality outcomes for the four inclusion health populations of interest
418 (substance use disorders, homeless populations, prisoners, and sex workers). The
419 studies identified described the highly overlapping nature of inclusion health
420 populations, the increased risk factors for disease, and poor mortality outcomes
421 compared with the general population.

422 423 *Added value of this study*

424 Our systematic review and meta-analysis provides the most comprehensive
425 examination to date of morbidity and mortality outcomes across a range of inclusion
426 health populations. We find that the extent of the health ~~inequalities inequity~~ seen in

427 inclusion health populations greatly exceeds that observed when comparing the richest and poorest neighbourhoods high
428 and low socioeconomic groups. Extremely high mortality rates are seen across ICD-
429 10 disease categories, with relative risks consistently higher in females than males.
430 The relative mortality excess is greatest for injury, poisoning and external causes.
431 However there is also high, although less extreme, relative mortality inequalities inequity across
432 more common disease categories such as cardiovascular disease and cancer. Non-
433 communicable diseases and injury, poisoning and external causes were lacking in
434 data despite the high summary Standardised Mortality Ratio estimates. Sex workers
435 were a particularly under-researched group.

436 *Implications of all the available evidence*

437 The extreme burden of disease experienced by inclusion health populations
438 demands a cross-sectoral response to prevent deep social exclusion and an
439 improvement in services working with these populations. This study provides the
440 most comprehensive assessment to date of the scale and distribution of mortality in
441 inclusion health populations in high-income countries. Our research focused on
442 relative measures of mortality and therefore future work should examine absolute
443 measures in greater detail. Inclusion health populations are often invisible within
444 routine health data. This limitation can be tackled by either modifying the instruments
445 used to collect such data or through data linkage studies. Services providing for
446 inclusion health populations should aim to deliver health and social services for
447 overlapping marginalised groups, in order to tackle the poor health outcomes found
448 in this study. These services should also have a greater focus on prevention and
449 management of more common conditions in addition to those traditionally considered
450 high risk for inclusion health groups.
451

452 **Contributors**

453 RWA, ACH and AS proposed the hypothesis and idea for the systematic review with
454 all authors contributing to its development and the analysis plan. RWA did the
455 literature search. RWA reviewed studies for inclusion. RWA, SL, ET, SVK, GH
456 performed the data extraction and checking. RWA performed all meta-analyses and
457 wrote the first draft of the manuscript. All authors reviewed and interpreted the
458 results and edited the manuscript.
459

460 **Declaration of interests**

461 ACH is a trustee of the Pathway: Healthcare for homeless people charity. AS is
462 Clinical Lead and Manager for Find&Treat.
463

464 **Acknowledgments**

465 RWA is supported by an academic clinical lectureship from the UK National Institute
466 for Health Research (NIHR). ACH's salary is provided by Central and North West
467 London NHS Community Trust. ET and SVK are funded by the Medical Research
468 Council (MC_UU_12017/13 and MC_UU_12017/15) and Chief Scientist's Office
469 (SPHSU13 and SPHSU15). AS is funded by UCLH Foundation Trust. SVK is also
470 funded by a NRS Scottish Senior Clinical Fellowship (SCAF/15/02). The views
471 expressed are those of the authors and not necessarily those of the Wellcome Trust,
472

476 NIHR, NHS, NHS Research Scotland, Medical Research Council, Chief Scientist's
477 Office.

478

479

480

481

482

483 **References**

484

485 1 Romeri E, Baker A, Griffiths C. Mortality by deprivation and cause of death in England and Wales,
486 1999-2003. *Health Stat Q* 2006; : 19–34.

487 2 Lankelly Chase | Hard Edges: Mapping Severe and Multiple Disadvantage in England.
488 <http://lankellychase.org.uk/multiple-disadvantage/publications/hard-edges/> (accessed Dec 2,
489 2016).

490 3 Fazel S., Bains P., Doll H. Substance abuse and dependence in prisoners: A systematic review.
491 2006.

492 4 Gilchrist G, Singleton N, Donmall M, Jones A. Prevalence and factors associated with sex trading in
493 the year prior to entering treatment for drug misuse in England. *Drug Alcohol Depend* 2015; **152**:
494 116–22.

495 5 Greenberg GA, Rosenheck RA. Homelessness in the state and federal prison population. *Crim*
496 *Behav Ment Health CBMH* 2008; **18**: 88–103.

497 6 Croxford S, Platt L, Hope VD, Cullen KJ, Parry JV, Ncube F. Sex work amongst people who inject
498 drugs in England, Wales and Northern Ireland: Findings from a National Survey of Health Harms
499 and Behaviours. *Int J Drug Policy* 2015; **26**: 429–33.

500 7 Fitzpatrick S, Bramley G, Johnsen S. Pathways into Multiple Exclusion Homelessness in Seven UK
501 Cities. *Urban Stud* 2013; **50**: 148–68.

502 8 Graham L, Fischbacher CM, Stockton D, Fraser A, Fleming M, Greig K. Understanding extreme
503 mortality among prisoners: a national cohort study in Scotland using data linkage. *Eur J Public*
504 *Health* 2015; **25**: 879–85.

505 9 Arendt M., Munk-Jorgensen P., Sher L., Jensen S.O.W. Mortality among individuals with cannabis,
506 cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish
507 substance users in treatment. 2011.

508 10 Nielsen SF, Hjorthøj CR, Erlangsen A, Nordentoft M. Psychiatric disorders and mortality among
509 people in homeless shelters in Denmark: a nationwide register-based cohort study. *Lancet* 2011;
510 **377**: 2205–14.

511 11 Peace R. Social exclusion: A concept in need of definition? *Soc Policy J N Z* 2001; : 17–36.

512 12 Fitzpatrick S, Bramley G, Johnse S. Multiple Exclusion Homelessness.
513 [http://mcnevaluation.co.uk/download/public/observatory/resource-type/research-](http://mcnevaluation.co.uk/download/public/observatory/resource-type/research-evaluation/2012%20Multiple%20Exclusion%20Homelessness%20-%20breifing%20paper%201.pdf)
514 [evaluation/2012%20Multiple%20Exclusion%20Homelessness%20-%20breifing%20paper%201.pdf](http://mcnevaluation.co.uk/download/public/observatory/resource-type/research-evaluation/2012%20Multiple%20Exclusion%20Homelessness%20-%20breifing%20paper%201.pdf)
515 (accessed Dec 2, 2016).

516 13 World Bank Country and Lending Groups – World Bank Data Help Desk.
517 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
518 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups) (accessed Nov 2, 2016).

519 14 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**:
520 1539–58.

- 521 15 Gilles M, Swingler E, Craven C, Larson A. Prison health and public health responses at a regional
522 prison in Western Australia. *Aust N Z J Public Health* 2008; **32**: 549–53.
- 523 16 Des Jarlais DC, Perlis T, Arasteh K, *et al.* Reductions in hepatitis C virus and HIV infections among
524 injecting drug users in New York City, 1990-2001. *AIDS Lond Engl* 2005; **19 Suppl 3**: S20-25.
- 525 17 del Amo J, González C, Losana J, *et al.* Influence of age and geographical origin in the prevalence
526 of high risk human papillomavirus in migrant female sex workers in Spain. *Sex Transm Infect* 2005;
527 **81**: 79–84.
- 528 18 Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural
529 nonmedical opioid analgesic users. *Drug Alcohol Depend* 2007; **87**: 98–102.
- 530 19 Bart G, Piccolo P, Zhang L, Jacobson I, Schaefer RA, Kreek MJ. Markers for hepatitis A, B and C in
531 methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. *Addict*
532 *Abingdon Engl* 2008; **103**: 681–6.
- 533 20 Carbonara S, Babudieri S, Longo B, *et al.* Correlates of Mycobacterium tuberculosis infection in a
534 prison population. *Eur Respir J* 2005; **25**: 1070–6.
- 535 21 Tabuchi T, Takatorige T, Hirayama Y, *et al.* Tuberculosis infection among homeless persons and
536 caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study. *BMC Infect Dis*
537 2011; **11**: 22.
- 538 22 Prinsloo B., Parr C., Fenton J. Mental illness among the homeless: Prevalence study in a Dublin
539 homeless hostel. *Ir. J. Psychol. Med.* 2012.
540 <http://www.ijpm.ie/1uvimm6u7uv?a=5&p=24612705&t=21297075>.
- 541 23 Lubman DI, Allen NB, Rogers N, Cementon E, Bonomo Y. The impact of co-occurring mood and
542 anxiety disorders among substance-abusing youth. *J Affect Disord* 2007; **103**: 105–12.
- 543 24 Baillargeon J, Penn JV, Thomas CR, Temple JR, Baillargeon G, Murray OJ. Psychiatric disorders and
544 suicide in the nation's largest state prison system. *J Am Acad Psychiatry Law* 2009; **37**: 188–93.
- 545 25 Vergara-Moragues E, González-Saiz F, Lozano OM, *et al.* Psychiatric comorbidity in cocaine users
546 treated in therapeutic community: substance-induced versus independent disorders. *Psychiatry*
547 *Res* 2012; **200**: 734–41.
- 548 26 Darke S, Williamson A, Ross J, Teesson M. Attempted suicide among heroin users: 12-month
549 outcomes from the Australian Treatment Outcome Study (ATOS). *Drug Alcohol Depend* 2005; **78**:
550 177–86.
- 551 27 O'Brien KK, Schuttke A, Alhakeem A, *et al.* Health, perceived quality of life and health services use
552 among homeless illicit drug users. *Drug Alcohol Depend* 2015; **154**: 139–45.
- 553 28 Brown RT, Kiely DK, Bharel M, Mitchell SL. Geriatric syndromes in older homeless adults. *J. Gen.*
554 *Intern. Med.* 2012.
- 555 29 Degenhardt L, Larney S, Randall D, Burns L, Hall W. Causes of death in a cohort treated for opioid
556 dependence between 1985 and 2005. *Addict Abingdon Engl* 2014; **109**: 90–9.

- 557 30 Harzke AJ, Baillargeon JG, Pruitt SL, Pulvino JS, Paar DP, Kelley MF. Prevalence of chronic medical
558 conditions among inmates in the Texas prison system. *J Urban Health Bull N Y Acad Med* 2010;
559 **87**: 486–503.
- 560 31 Kapilashrami A, Hill S, Meer N. What can health inequalities researchers learn from an
561 intersectionality perspective? Understanding social dynamics with an inter-categorical approach?
562 *Soc Theory Health* 2015; **13**: 288–307.
- 563 32 Ioannidis JPA, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in
564 forest plots. *BMJ* 2008; **336**: 1413–5.
- 565 33 The Marmot Review. Fair Society, Healthy Lives. 2010; published online Feb.
- 566 34 Katikireddi SV, Valles SA. Coupled Ethical-Epistemic Analysis of Public Health Research and
567 Practice: Categorizing Variables to Improve Population Health and Equity. *Am J Public Health*
568 2015; **105**: e36–42.
- 569 35 Aldridge RW, Shaji K, Hayward AC, Abubakar I. Accuracy of Probabilistic Linkage Using the
570 Enhanced Matching System for Public Health and Epidemiological Studies. *PLoS One* 2015; **10**:
571 e0136179.
- 572 36 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity
573 and implications for health care, research, and medical education: a cross-sectional study. *Lancet*
574 *Lond Engl* 2012; **380**: 37–43.
- 575 37 Roy E, Haley N, Boudreau J-F, Leclerc P, Boivin J-F. The challenge of understanding mortality
576 changes among street youth. *J Urban Health Bull N Y Acad Med* 2010; **87**: 95–101.
- 577 38 Vila-Rodriguez F, Panenka WJ, Lang DJ, et al. The hotel study: multimorbidity in a community
578 sample living in marginal housing. *Am J Psychiatry* 2013; **170**: 1413–22.
- 579 39 Kariminia A, Butler TG, Corben SP, et al. Extreme cause-specific mortality in a cohort of adult
580 prisoners--1988 to 2002: a data-linkage study. *Int J Epidemiol* 2007; **36**: 310–6.
- 581 40 Pratt D, Piper M, Appleby L, Webb R, Shaw J. Suicide in recently released prisoners: a population-
582 based cohort study. *Lancet Lond Engl* 2006; **368**: 119–23.
- 583 41 Arendt M., Munk-Jorgensen P., Sher L., Jensen S.O.W. Mortality among individuals with cannabis,
584 cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish
585 substance users in treatment. *Drug Alcohol Depend*. 2011.
- 586 42 Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality and its impact on adult mortality
587 in eight European countries. *Eur J Public Health* 2006; **16**: 198–202.
- 588 43 Barrio G, Molist G, de la Fuente L, et al. Mortality in a cohort of young primary cocaine users:
589 controlling the effect of the riskiest drug-use behaviors. *Addict Behav* 2013; **38**: 1601–4.
- 590 44 Bjornaas MA, Bekken AS, Ojlert A, et al. A 20-year prospective study of mortality and causes of
591 death among hospitalized opioid addicts in Oslo. *BMC Psychiatry* 2008; **8**: 8.
- 592 45 Darke S, Mills KL, Ross J, Teesson M. Rates and correlates of mortality amongst heroin users:
593 findings from the Australian Treatment Outcome Study (ATOS), 2001-2009. *Drug Alcohol Depend*
594 2011; **115**: 190–5.

- 595 46 Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug
596 users in San Francisco: a 10-year follow-up of the UFO study. *Am J Epidemiol* 2012; **175**: 302–8.
- 597 47 Gibson A., Randall D., Degenhardt L. The increasing mortality burden of liver disease among
598 opioid-dependent people: cohort study. *Addict*. Abingdon Engl. 2011.
- 599 48 Hser Y.I., Kagihara J., Huang D., Evans E., Messina N. Mortality among substance-using mothers in
600 California: a 10-year prospective study. *Addict*. Abingdon Engl. 2012.
- 601 49 Lee CTC, Chen VCH, Tan HKL, *et al.* Suicide and other-cause mortality among heroin users in
602 Taiwan: a prospective study. *Addict Behav* 2013; **38**: 2619–23.
- 603 50 Merrall ELC, Bird SM, Hutchinson SJ. Mortality of those who attended drug services in Scotland
604 1996-2006: record-linkage study. *Int J Drug Policy* 2012; **23**: 24–32.
- 605 51 Nyhlen A., Fridell M., Backstrom M., Hesse M., Krantz P. Substance abuse and psychiatric co-
606 morbidity as predictors of premature mortality in Swedish drug abusers a prospective longitudinal
607 study 1970 - 2006. *BMC Psychiatry*. 2011. <http://www.biomedcentral.com/1471-244X/11/122>.
- 608 52 Nyhlen A., Fridell M., Hesse M., Krantz P. Causes of premature mortality in Swedish drug abusers:
609 A prospective longitudinal study 1970-2006. *J. Forensic Leg. Med.* 2011.
- 610 53 Pavarin RM. Mortality risk for cocaine abusers in relation to heroin use: a follow-up study. *Subst*
611 *Use Misuse* 2013; **48**: 702–10.
- 612 54 Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted
613 treatment in Switzerland 1994-2000. *Drug Alcohol Depend* 2005; **79**: 137–43.
- 614 55 Rosca P, Haklai Z, Goldberger N, Zohar P, Margolis A, Ponizovsky AM. Mortality and causes of
615 death among users of methadone maintenance treatment in Israel, 1999-2008. *Drug Alcohol*
616 *Depend* 2012; **125**: 160–3.
- 617 56 Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among amphetamine users: A
618 systematic review of cohort studies. 2009.
- 619 57 Spittal PM, Hogg RS, Li K, *et al.* Drastic elevations in mortality among female injection drug users
620 in a Canadian setting. *AIDS Care* 2006; **18**: 101–8.
- 621 58 Stoové MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a
622 16-year follow-up of the Victorian Injecting Cohort Study (VICS). *Drug Alcohol Depend* 2008; **96**:
623 281–5.
- 624 59 van Santen DK, van der Helm JJ, Grady BPX, *et al.* Temporal trends in mortality among people who
625 use drugs compared with the general Dutch population differ by hepatitis C virus and HIV
626 infection status. *AIDS Lond Engl* 2014; **28**: 2589–99.
- 627 60 Zabransky T., Csemy L., Grohmannova K., Janikova B., Brenza J. Mortality of cohort of very young
628 injecting drug users in Prague, 1996-2010. *Cent. Eur. J. Public Health*. 2011.
- 629 61 Randall D., Degenhardt L., Vajdic C.M., *et al.* Increasing cancer mortality among opioid-dependent
630 persons in Australia: a new public health challenge for a disadvantaged population. *Aust. N. Z. J.*
631 *Public Health*. 2011.

- 632 62 Degenhardt L., Singleton J., Calabria B., *et al.* Mortality among cocaine users: A systematic review
633 of cohort studies. *Drug Alcohol Depend.* 2011.
- 634 63 Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide
635 opioid pharmacotherapy program over 20 years: risk factors and lives saved. *Drug Alcohol Depend*
636 2009; **105**: 9–15.
- 637
- 638

639 **Tables**

640

641 **Table 1. Characteristics of studies included in Standardised Mortality Ratio**
642 **meta-analyses.**

643

Author	Population	Population Description	Number of Participants	Country	Study Years
Nielsen ¹⁰	Homeless	Females aged 16yr or more with at least one contact with a homeless shelter	32711	Denmark	1999-2009
Roy ³⁷	Homeless	Young people aged 14-25 who were "street active"	829	Canada	1995-2001
Vila-Rodriguez ³⁸	Homeless	A prospective community sample of adults living in single-room occupancy hotel	293	Canada	2008-2011
Graham ⁸	Prisoners	Males imprisoned for the first time between 1996 and 2007	76627	United Kingdom	1996-2007
Kariminia ³⁹	Prisoners	All adults who had experienced full-time custody	85203	Australia	1988-2002
Pratt ⁴⁰	Prisoners	All sentenced and remanded prisoners released from prison	244988	United Kingdom	1999-2002
Arendt ⁴¹	SUD	People receiving treatment in 'specialist institutions' for substance use disorder, reporting cocaine as their primary substance	20581	Denmark	1996-2006
Bargagli ⁴²	SUD	Male opiate users aged 15-69 entering treatment	2575	Netherlands	1996-2002
Barrio ⁴³	SUD	Regular cocaine users recruited from drug scenes and non-treatment settings	714	Spain	2004-2006
Bjornaas ⁴⁴	SUD	Individuals with opioid addiction hospitalised due to self-poisoning	185	Norway	1980-2000
Darke ⁴⁵	I	Opioid users	615	Australia	2001-2009
Degenhardt ²⁹	SUD	Opioid-dependent people treated with opioid substitution therapy	43789	Australia	1985-2005
Evans ⁴⁶	SUD	Young (<30yrs) injecting drug users	644	United States	2005-2007
Gibson ⁴⁷	SUD	Opioid users	2489	Australia	1980-2006
Hser ⁴⁸	SUD	Women who were admitted to drug-treatment programs	4447	United States	2000-2002
Lee ⁴⁹	SUD	Heroin users attending for opioid substitution therapy	10842	Taiwan	2006-2008
Mathers ⁵⁰	SUD	People who injected opioids and other drugs	101	Denmark	1980-1999
Merrall ⁵⁰	SUD	People in contact with drug treatment services	69456	United Kingdom	1996-2006
Nyhlen ^{51,52}	SUD	Substance abusers admitted for inpatient detoxification	561	Sweden	1970-2006
Pavarin ⁵³	SUD	Individuals who had visited a public treatment center for problems due to the use/abuse of cocaine	471	Italy	1988-2012

Rehm ⁵⁴	SUD	Participants in heroin-assisted treatment	6281	Switzerland	1994-2000
Rosca ⁵⁵	SUD	Patients who had ever been treated or were currently in treatment in methadone maintenance treatment clinics	9818	Israel	1999-2008
Singleton ⁵⁶	SUD	Drug users admitted to hospital for drug related problems	3039	Czech Republic	1997-2002
Spittal ⁵⁷	SUD	Injection drug users recruited through self-referral and street outreach	520	Canada	1996-2002
Stoove ⁵⁸	SUD	Injection drug users recruited through the social networks of 'privileged access' interviewers	220	Australia	1990-2006
van Santen ⁵⁹	SUD	Individuals from local methadone outposts, a sexually transmitted diseases clinic, and word of mouth.	1254	Netherlands	1985-2012
Zabransky ⁶⁰	SUD	Injecting drug users younger than nineteen and older than fifteen years of age.	151	Czech Republic	1996-2008
Randall ⁶¹	SUD	All persons who came into contact with the New South Wales Opioid Substitution therapy program	43789	Australia	1985-2005
Degenhardt ⁶²	SUD	Canadian cohort of daily cocaine injectors	717	Canada	1996-2004
Degenhardt ⁶³	SUD	Opioid users	42676	Australia	1985-2006

646
647
648

Table 2. Number of studies and data points included in the systematic review and results of meta-analysis of standardised mortality ratios

Commented [RA7]: To complete and double check with text

ICD-10 chapter	Number of studies	Total number of data points (% of all data points)	Number of mortality data points (% of all mortality data points)
Total	337	2835 (100)	336 (100)
All-cause	32	140 (5)	92 (27) 34
Infectious and parasitic diseases	160	898 (32)	21 (6)
Neoplasms	4	145 (5)	41 (12)
Blood		18 (1)	--
Endocrine		66 (2)	6 (2)
Mental and behavioural disorders	90	715 (25)	6 (2)
Nervous system		43 (2)	6 (2)
Eye and adenexa		14 (0)	-
Ear		4 (0)	-
Diseases of the circulatory system	44	149 (5)	17 (2)
Respiratory system		79 (3)	8 (2)
Digestive system		82 (3)	34 (10)
Skin		44 (2)	-
Musculoskeletal		29 (1)	-
Injury, + poisoning and certain external causes		98 (3)	44 (13)
External causes		207 (7)	61 (18)
Other			

649


650

651 **Figures**

652

653 **Figure 1. Flowchart of included studies**

654




655

656



657

Figure 2. Geographical spread of existing data from high-income countries on homeless populations.



Included countries: Australia, Austria, Belgium, Canada, Chile, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Uruguay

Figure 32. Treemap summarising amount of data by ICD-10 chapter and summary estimates of SMR




Note: Size of box indicates number of data points included (e.g. Infectious and parasitic disease = 953; Disease of Nervous system = 43). SMR used is summary estimate for ICD-10 chapter for both sexes combined. Boxes without labels are **1=Genitourinary**; **2=Musculoskeletal**; **13=symptoms, signs and abnormal clinical and laboratory findings**; **42=Ear and Mastoid process**; and **53=Eye and Adnexa**; **4=**. Grey boxes (with an SMR of '0') indicate that none of the studies included in this review reported SMR.

Commented [D8]: There was still one label missing. Looking at the ICD10 chapters, I'm guessing it's diseases of the blood?


Commented [RA9]: ? Blood – to check and update before submission

Figure 43. Standardised Mortality Ratios for all-cause mortality



Note: Weights are from random effects analysis. Several studies contribute multiple rows of data due to different: SUD groups included (Arendt and Pavarin); countries (Bargagli); or time periods (Merrall).

Figure 54. Standardised Mortality Ratios by ICD-10 category (excluding those due to injury and external causes).



Note: Weights are from random effects analysis. SMRs greater than 60 are excluded for presentational purposes. Several studies contribute multiple rows of data due to different: outcomes (Graham; Pavarin; Karimina; Randall and Gibson) and time periods included (Merrall).

